Puma Biotechnology stock fell 1.76 percent after award news

Published on 10/07/2026 at 06:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Puma Biotechnology granted 7,500 inducement shares on October 1, 2026. Its Q2 2026 EPS reached USD 0.19 against USD 0.04 consensus.

PBYI, US74587V1070, Illustration mit AI erstellt.

Puma Biotechnology (ISIN US74587V1070) stock was last at USD 9.50 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 1.76 percent from USD 9.67. The latest company event was a 7,500-share inducement award approved on October 1, 2026.

7,500 shares approved

According to StockTitan on October 5, 2026, Puma granted restricted stock units covering 7,500 common shares to one new non-executive employee. The award vests over three years and was issued under the company's 2017 Employment Inducement Incentive Award Plan.

The award is small relative to Puma's equity base, but it gives the October news flow a concrete corporate action. The filing also confirms Puma's continued use of equity incentives for new employees under Nasdaq Listing Rule 5635(c)(4).

Q2 earnings beat consensus

MarketBeat reports that Puma's second-quarter 2026 earnings released on August 6 delivered quarterly EPS of USD 0.19, compared with USD 0.04 consensus. Revenue reached USD 56.50 million versus USD 53 million expected.

The EPS surprise was USD 0.15 per share, while revenue exceeded consensus by USD 3.50 million. These figures give the stock a stronger operating reference than the latest equity award alone, although the market's valuation still depends heavily on Puma's oncology pipeline.

Alisertib expands the pipeline

According to StockTitan, Puma initiated the ALISCA-Lung2 Phase II trial in September 2026. The study combines alisertib with paclitaxel for patients with advanced small cell lung cancer.

Puma also markets NERLYNX, an oral therapy for HER2-positive breast cancer, and holds development rights to alisertib. The combination of an established commercial product and mid-stage clinical programs leaves trial progress as a central company-specific valuation factor.

Consensus target remains USD 6

MarketBeat lists a Hold consensus based on two analysts, with an average, high and low price target of USD 6.00. The published target is below the October 6 Nasdaq price, making the quarterly earnings beat a key counterweight to the cautious consensus.

Stock stays below yearly high

Puma Biotechnology stock was last at USD 9.50 on Nasdaq on October 6, 2026, 5.94 percent below its 52-week high of USD 10.10. Its market capitalization was USD 483.5 million, with volume of 322,655 shares.